European association of nuclear medicine procedure guidelines for brain imaging using [18F]FDG

European Journal of Nuclear Medicine

Volumn 29, Issue 10, 2002, Pages

  Bartenstein, P ^a   Asenbaum, S ^a   Catafau, A ^a   Halldin, C ^a   Pilowski, L ^a   Pupi, A ^a   Tatsch, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; ADENOSINE TRIPHOSPHATE;

ANAMNESIS; BRAIN METABOLISM; BRAIN SCINTISCANNING; BRAIN TUMOR; COMPARATIVE STUDY; DEMENTIA; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DOSIMETRY; EPILEPSY; ERROR; EUROPE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; INFORMATION PROCESSING; MEDICAL SOCIETY; NEUROLOGY; NUCLEAR MEDICINE; PATIENT CARE; PATIENT INFORMATION; PATIENT POSITIONING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREGNANCY; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; STANDARD; VISUAL INFORMATION; ARTICLE; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; INTERNATIONAL COOPERATION; METHODOLOGY; SCINTISCANNING; MEDICAL PRACTICE; PHOSPHORYLATION; PHYSICIAN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOPOGRAPHY;

BRAIN; EUROPE; FLUORODEOXYGLUCOSE F18; HUMANS; INTERNATIONAL COOPERATION; NUCLEAR MEDICINE; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; SOCIETIES, MEDICAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036381962     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Kuwert T, Bartenstein P, Grünwald F, et al. Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference. Nervenarzt 1989; 69:1045-1160.
2. Asenbaum S. Guideline for the use of FDG PET in Neurology and Psychiatry. Austrian Society of Nuclear Medicine 2001; www.ogn.at
3. Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998; 39:1302-1305.
4. Society of Nuclear Medicine Brain Imaging Council. Ethical clinical practice of functional brain imaging. J Nucl Med 1996; 37:1256-1259.
5. Messa C, Fazio F, Costa DC, Ell PJ. Clinical brain radionuclide imaging. Semin Nucl Med 1995; 25:111-143.
6. Setani K, Schreckenberger M, Sabri O, et al. Comparison of different methods for attenuation correction in brain PET: effect on the calculation of the metabolic rate of glucose. Nuklearmedizin 2000; 39:50-55.
7. Devous JS. Imaging and epilepsy. Brain 1997; 120:339-377.
8. Chugani HA. Functional brain imaging in pediatrics. Pediatr Clin North Am 1992: 39:777-799.
9. Jelic V, Nordberg A. Early diagnosis of Alzheimer disease with positron emission tomography. Alzheimer Dis Assoc Disord 2000; 14 Suppl 1:S109-S113.
10. Herholz K. FDG PET and differential diagnosis of dementia. Alzheim Dis Assoc Disord 1995; 9:6-16.
11. Kerwin R. Functional neuroimaging in Alzheimer's disease: how far should we go? Eur J Nucl Med 1994; 21:1041-1043.
12. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39:778-785.
13. Hasselbalch SG, Knudsen GM, Videbaek C, et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999; 48:1915-1921.
14. Cranston I, Marsden P, Matyka K, et al. Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood Flow Metab 1998; 18: 130-140.
15. Spanaki MV, Siegel H, Kopylev L, et al. The effect of vigabatrin (gamma-vinyl GabA) on cerebral blood flow and metabolism. Neurology 1999; 53:1518-1522.
16. Ruotsalainen U, Suhonen-Polvi H, Eronen E, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med 1996; 37:387-393.
17. Lucignani G, Schmidt KC, Moresco RM, et al. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. J Nucl Med 1993; 34:360-369.
18. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000; 41:661-681.
19. Henry TR, Engel J Jr, Mazziotta JC. Clinical evaluation of interictal fluorine-18-fluordeoxyglucose PET in partial epilepsy. J Nucl Med 1993; 34:1892-1898.
20. Schreckenberger M, Spetzger U, Sabri O, et al. Localisation of motor areas in brain tumour patients: a comparison of preoperative 18-FDG-PET and intraoperative cortical electrostimulation. Eur J Nucl Med 2001; 28:1394-1403.
21. Herholz K, Pietrzyk U, Karbe H, et al. Individual metabolic anatomy of repeating words demonstrated by MRI-guided positron emission tomography. Neurosci Lett 1994; 182:47-50.
22. Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med 1993; 34:322-329.
23. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with F-18 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6:371-388.
24. Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36:1238-1248.
25. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Human brain function. London: Academic Press, 1997.
26. Drzezga A, Arnold S, Minoshima S, et al. F-18 FDG-PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999; 40:737-746.
27. 18F]FDG PET: a clinical validation of statistical parametric mapping. Neuroimage 1999; 9:63-80.
28. Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999; 26:1363-1378.